TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

Key Points

• Kidney transplantation is TransMedics’ largest growth initiative: The company estimates its OCS kidney program could address nearly 30,000 annual procedures, with potential pricing of $40,000–$45,000 per case plus logistics and reimbursement through CMS.
• TransMedics reiterated 2025 revenue guidance of $737 million to $757 million, representing 22%–25% growth, while targeting an adjusted operating margin near 30% by 2028 or after reaching 10,000 transplants.
• The company is expanding internationally through its PAD Aviation acquisition, which provides a license to bid on European transplant-logistics tenders, while also pursuing broader heart and lung adoption and next-generation OCS studies.

TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.

Waleed Hassanein, TransMedics’ president, CEO and founder, said the company has built a vertically integrated organ transplantation platform intended to increase the availability of donor organs and improve transplant outcomes. The platform includes its Organ Care System, or OCS, the National OCS Program procurement network, dedicated air and ground logistics, the NOP Connect digital platform, and donor and recipient screening services.

Hassanein said TransMedics operates from 20 U.S. hubs, owns and operates 22 aircraft dedicated to organ transplant missions, and employs about 50 procurement surgeons and staff as well as more than 250 clinical coordinators and specialists.

The company said it has averaged 86% compound annual revenue growth over the last three years, is profitable and generates free cash flow. It ended its most recent quarter with more than $472 million on its balance sheet and reiterated annual revenue guidance of $737 million to $757 million, representing growth of 22% to 25%.

Margin Outlook and Kidney Investment

During the fireside chat, Hassanein and Chief Financial Officer Gerardo Hernandez addressed investor questions surrounding the company’s profitability targets and increased investment spending.

Hernandez said TransMedics continues to expect to reach, or approach, a 30% adjusted operating margin by 2028 or when it reaches 10,000 transplants. He said the company’s 2026 operating-margin guidance of 12.5% to 14% incorporates planned spending for the year, with incremental investment in the OCS kidney program accounting for much of the step-up in expenses.

For 2027, Hernandez said operating expenses are expected to rise by roughly the low teens, rather than at the higher rate seen in 2026. He said the company expects an acceleration in growth and improvement in operating margin next year.

Kidney transplantation is among TransMedics’ principal growth initiatives. Hassanein said there were approximately 21,000 deceased-donor kidney transplants in the U.S. last year, while nearly 10,000 kidneys were discarded because of extended preservation time. He said the company believes its kidney program could address close to 30,000 annual procedures.

Hassanein said the kidney opportunity is supported by potential savings for the Centers for Medicare & Medicaid Services. He cited an estimated $10.5 billion annual cost for maintaining roughly 100,000 patients on the national kidney waiting list, along with an estimated $150 million to $250 million in annual costs related to delayed graft function following transplantation.

He said OCS kidney pricing could be in the range of $40,000 to $45,000 plus logistics costs, rather than the price levels associated with some of the company’s existing organ programs. According to Hassanein, the company expects kidney-related costs to be reimbursable as organ acquisition costs, with CMS serving as the payer.

International Expansion and Aviation Strategy

TransMedics also discussed its expansion into Europe, including its acquisition of PAD Aviation. Hassanein said the company acquired PAD primarily to obtain the operating license needed to bid on European transplant-logistics tenders, rather than to operate it as a traditional charter business.

“PAD is only acquiring a license so we can bid on tens of millions of EUR tenders,” Hassanein said.

He said PAD has six leased aircraft and does not own aircraft. TransMedics does not plan to make substantial capital investments in aircraft until it sees sufficient demand and tender awards, he said. The company expects PAD to have a small, temporary near-term effect on profit and loss results and plans to discuss its financial performance in more detail during its third-quarter call.

Hassanein said the goal is to transition PAD into a transplant-focused logistics business within the TransMedics Aviation group.

OCS Adoption, Regulatory Studies and OPO Opportunity

The company identified further heart and lung adoption as another growth opportunity. Hassanein said TransMedics is pursuing access to more than 5,200 to 5,400 annual U.S. heart and lung cases through both the OCS platform and CHOPS, a lower-priced cold-preservation technology.

On the status of CHOPS, Hassanein said a competitor’s decision not to compare its technology against OCS led TransMedics to revise the planned study. The company now expects to conduct a 600-patient study using its own platform, including 200 CHOPS cases and 400 OCS cases.

Hassanein also addressed questions about the potential for TransMedics to obtain an organ procurement organization, or OPO, license. He said the decision rests with CMS and the Health Resources and Services Administration and that the company is not relying on an OPO designation in its operating plans.

If TransMedics does not receive an OPO license, “nothing changes,” Hassanein said, adding that the company would continue its existing strategy. If selected, he said the company believes its integrated procurement, preservation and logistics platform could help make more organs available to patients.

Finally, Hassanein said the company saw no increase in “dry runs” during the second quarter and that such cases had no impact on its quarterly revenue or performance. He described dry runs as donor cases that do not ultimately materialize.

Management said its strategic investments are intended to support a path toward a multibillion-dollar revenue base, with Hassanein citing a long-term opportunity of more than $2 billion in revenue.

About TransMedics Group (NASDAQ:TMDX)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source